PDCD1 and melanoma: One of the principal motivations behind many of these trials were the early results combining these MAbs in the context of advanced melanoma, where Phase II and III studies clearly demonstrated the greater efficacy of the antibody combination over monotherapy (and also showing the better efficacy of anti-PD-1 over anti-CTLA-4 monotherapies).